









Markets
/
Stocks
/
nasdaq-pfe
/

Pfizer Inc

PFE



View Detailed Chart

23.870USD

-0.980-3.94%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

135.70BMarket Cap

12.62P/E TTM



Pfizer Inc

23.870

-0.980-3.94%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-3.94%

5 Days

-4.06%

1 Month

-4.94%

6 Months

-7.19%

Year to Date

-10.03%

1 Year

-18.45%

View Detailed Chart

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

47 / 176

Overall Ranking

157 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 27 analysts

Hold

Current Rating

29.130

Target Price

+22.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.

Fairly Valued

The company’s latest PE is 12.60, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.85B shares, decreasing 2.26% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 530.68M shares of this stock.

News

Trump executive order demands pharma industry price cuts

WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.

ReutersTue, May 13

Trump Plans Major Drug Price Cuts, Pharma Stocks Tumbles

Trump signals an executive order to slash drug prices, causing a sharp sell-off in Asian pharmaceutical stocks. Major companies like Johnson & Johnson, Pfizer, and Abbott could be hit hard.

TradingKeyMon, May 12

The Strategic Repositioning Driving Pfizer's Growth Story

TradingKey - Pfizer’s non-COVID portfolio grew 12% in 2024, led by a 65% surge in Vyndaqel sales and 26% oncology revenue growth.

TradingKeyTue, Apr 8

Pfizer sells entire Haleon stake for $3.24 billion

March 19 (Reuters) - Drugmaker Pfizer PFE.N has sold its entire stake in Haleon HLN.L for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday.

ReutersWed, Mar 19